Service d'Urologie, Hôpital Foch, 40, rue Worth, 92151 Suresnes, France.
Three clinical cases have shown the superiority of sunitinib in first line therapy intermediate risk metastatic clear cell renal carcinoma and a best safety of bevacizumab plus interferon, the current lack of high level of evidence arguments for the neo-adjuvant treatment of kidney cancer, the importance to prevent mucositis during a mTOR inhibitors treatment and the diagnostic pitfalls of its pulmonary complications.
Article in French.
Written by:
Neuzillet Y, Guy L, Long JA, Zini L, Chevreau C, Duclos B, Escudier B, Gimel P, Joly F, Lang H, Mejean A, Oudard S, Roumeguere T. Are you the author?
Reference: Prog Urol. 2011 Mar;21 Suppl 2:S27-33.
doi: 10.1016/S1166-7087(11)70006-9
PubMed Abstract
PMID: 21397824
UroToday.com Renal Cancer Section
